FDA: Cell phones still look safeFebruary 11, 2020Mixed TopicsCNS/Brain CancerBreast CancerLung CancerLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationGynecologic Cancer
Adding ilixadencel improved outcomes in metastatic renal cell carcinomaFebruary 10, 2020Renal Cell Carcinoma
Global project reveals cancer’s genomic playbookFebruary 5, 2020Mixed TopicsCNS/Brain CancerBreast CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersHead & Neck/Thyroid CancersGynecologic Cancer
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumorsJanuary 31, 2020Renal Cell CarcinomaImmuno-oncologyGenitourinary CancerMelanomaLung CancerGynecologic CancerHead & Neck/Thyroid Cancers
RCC: Tivozanib beats sorafenib in later linesDecember 19, 2019Renal Cell CarcinomaGenitourinary Cancer
Atezolizumab/bevacizumab may offer benefit to patients with RCCNovember 25, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Sunitinib for mRCC: Real-world experience differs somewhatNovember 7, 2019Renal Cell CarcinomaGenitourinary Cancer
Ezrin negativity predicts poor prognosis in clear cell RCCOctober 31, 2019Renal Cell CarcinomaGenitourinary Cancer
Immunotherapy enables nephrectomy with good outcomes in advanced RCCOctober 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Cancer burden: Multiple metrics needed to clarify the big pictureOctober 4, 2019Breast CancerGastroenterologyMelanomaGenitourinary CancerRenal Cell CarcinomaGastrointestinal Cancer
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCCOctober 2, 2019Renal Cell CarcinomaImmuno-oncologyGenitourinary Cancer
PBRM1 mutations not quite up to snuff as ccRCC biomarkersSeptember 13, 2019Renal Cell CarcinomaGenitourinary Cancer
SABR offers surgery alternative for localized RCCSeptember 8, 2019Renal Cell CarcinomaGenitourinary Cancer
Nivolumab falls short in ccRCC patients with brain metastasesAugust 28, 2019Renal Cell CarcinomaImmunotherapyImmuno-oncology
Study outlines survival factors with nivolumabJuly 25, 2019Lung CancerRenal Cell CarcinomaMelanomaImmuno-oncology
